Novartis(NVS) - 2023 Q1 - Earnings Call Presentation

eBC – early breast cancer. ET – endocrine therapy. iDFS – invasive disease-free survival. 1. Unprobabilized peak sales. 2. Under stage II: N0, T0N1 is excluded; T2N0 only if G3, or G2 with Ki67≥20% or high risk on Oncotype DX / Prosigna / MammaPrint / EndoPredict. 3. Estimated incidence US + EU5. Sources: DRG (US) and Kantar (EU5). TNM and grade information based on SEER AJCC 8th Incidence Report. 9 NOVARTIS Q1 RESULTS | APRIL 25, 2023 | NOVARTIS INVESTOR PRESENTATION APPOINT-PNH: Single-arm Ph3 trial in ad ...